We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

139 hedge funds and large institutions have $1.17B invested in Avidity Biosciences in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 78 increasing their positions, 25 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,483% more call options, than puts

Call options by funds: $2.85M | Put options by funds: $180K

212% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0.55% less ownership

Funds ownership: 107.76% → 107.21% (-0.55%)

6% less funds holding

Funds holding: 148 → 139 (-9)

26% less capital invested

Capital invested by funds: $1.57B → $1.17B (-$404M)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

Holders
139
Holders Change
-9
Holders Change %
-6.08%
% of All Funds
2.22%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
15
Increased
78
Reduced
25
Closed
23
Calls
$2.85M
Puts
$180K
Net Calls
+$2.67M
Net Calls Change
+$5.08M

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$21.2M
2
State Street
State Street
Massachusetts
+$17.8M
3
RI
RTW Investments
New York
+$17.2M
4
Artisan Partners
Artisan Partners
Wisconsin
+$13.3M
5
BBA
Baker Bros. Advisors
New York
+$12.5M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$44.2M
2
Millennium Management
Millennium Management
New York
-$16.7M
3
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$10.2M
4
SCM
Soleus Capital Management
Connecticut
-$6.88M
5
DTC
Deep Track Capital
Connecticut
-$6.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$8.49M +$9.42M +428,066 +343%
Franklin Resources
27
Franklin Resources
California
$8.13M +$3.95M +179,666 +51%
AG
28
Artal Group
Luxembourg
$7.86M +$263K +11,962 +2%
FLSM
29
Frazier Life Sciences Management
California
$7.67M – – –
Charles Schwab
30
Charles Schwab
California
$7.5M +$545K +24,779 +5%
Bank of America
31
Bank of America
North Carolina
$6.24M +$3.57M +162,134 +66%
T. Rowe Price Investment Management
32
T. Rowe Price Investment Management
Maryland
$6.11M – – –
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$5.93M +$3.02M +137,189 +55%
OCA
34
Octagon Capital Advisors
New York
$5.86M +$1.26M +57,371 +18%
Rafferty Asset Management
35
Rafferty Asset Management
New York
$5.85M +$1.41M +63,978 +20%
Renaissance Technologies
36
Renaissance Technologies
New York
$5.76M +$4.59M +208,500 +125%
Barclays
37
Barclays
United Kingdom
$5.7M -$107K -4,857 -1%
Two Sigma Investments
38
Two Sigma Investments
New York
$5.04M +$4.88M +221,588 +207%
DCM
39
Driehaus Capital Management
Illinois
$4.81M -$830K -37,703 -11%
Norges Bank
40
Norges Bank
Norway
$4.46M +$4.52M +205,400 +241%
Citigroup
41
Citigroup
New York
$3.91M +$3.07M +139,726 +122%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$3.56M +$782K +35,555 +18%
N
43
Nuveen
North Carolina
$3.17M +$630K +28,617 +16%
Invesco
44
Invesco
Georgia
$2.56M +$2.15M +97,862 +142%
Deutsche Bank
45
Deutsche Bank
Germany
$2.53M +$288K +13,077 +9%
FAM
46
Fred Alger Management
New York
$2.42M -$402K -18,256 -10%
CS
47
Candriam SCA
Luxembourg
$2.4M -$902K -41,000 -19%
TD Asset Management
48
TD Asset Management
Ontario, Canada
$2.34M -$261K -11,847 -7%
Wellington Management Group
49
Wellington Management Group
Massachusetts
$2.21M +$120K +5,461 +4%
Two Sigma Advisers
50
Two Sigma Advisers
New York
$2.17M +$1.86M +84,400 +149%
1
2
3 4 5

RNAM Hedge Fund Activity: Q1 2023 in Review

139 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2023, worth a combined $1.17B — down 26% from $1.57B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of RNAM and 15 opened new positions — a net loss of 8 holders — while 25 trimmed existing stakes and 78 added.

The largest buyer was RA Capital Management, adding an estimated $21.2M. The largest seller was Avidity Partners Management, cutting an estimated $44.2M.

  • 139 institutional investors held Avidity Biosciences (RNAM) as of Q1 2023, down from 148 in Q4 2022.
  • Funds reported $1.17B of Avidity Biosciences stock for Q1 2023, down 26% quarter-over-quarter.
  • 15 funds opened new Avidity Biosciences positions in Q1 2023 and 23 closed out, a net change of -8 holders.
  • The largest Avidity Biosciences buyer in Q1 2023 was RA Capital Management, an estimated $21.2M added.
  • The largest Avidity Biosciences seller in Q1 2023 was Avidity Partners Management, an estimated $44.2M sold.

Based on aggregated 13F filings for Q1 2023.